Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...

Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...

Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.

On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...

Adding chemotherapy to osimertinib in patients with advanced non-small cell lung cancer (NSCLC) harboring concurrent EGFR and TP53 mutations more than doubled median progression-free survival (PFS) ...

The U.S. Food and Drug Administration (FDA) approved belzutifan (Welireg) in combination with lenvatinib (Lenvima) for adults ...

When it comes to treatment decisions for patients with EGFR-mutated non-small cell lung cancer, “the most important conversations are not the data-driven ones, they are the relational ones,” patient ...

At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...

Recent headlines on leadership appointments, executive transitions and notable recognitions spotlight the leaders helping to ...

Tarlatamab (Idella) provided meaningful intracranial activity without added safety concerns in a real-world analysis of patients with small cell lung cancer (SCLC) and brain metastases, including ...

Bundled payment models can offer employers more predictable cancer costs, but implementing them in community oncology can be complicated by financial risk and administrative demands. At the 2026 ...